(Total Views: 465)
Posted On: 03/30/2019 3:05:22 PM
Post# of 1418
Todos Medical Appoints Dr. Colin Bier to Its Board of Directors
March 27, 2019 at 8:00 AM EDT
REHOVOT, Israel, March 27, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced the appointment of Dr. Colin Bier to its Board of Directors. Dr. Bier has over 35 years of clinical expertise having participated in numerous clinical trials, including trials in Alzheimer's disease, as well as experience in commercializing diagnostic tests.
"Dr. Bier brings expertise to the Company in the commercialization of diagnostic tests, including navigating the intricacies of CLIA and the FDA, and bringing diagnostic tests to market," said Dr. Herman Weiss, CEO of Todos Medical. "As Dr. Bier has previously served in the roles of Scientific Advisor and Chief Development Officer of Amarantus Diagnostics, his familiarity with our recent joint venture surrounding the science of LymPro, a diagnostic test for Alzheimer’s Disease, makes Colin an immediate asset to our organization. We believe his experience will be highly valuable as we navigate the regulatory landscape and seek to bring our diagnostic tests to the broader physician-patient community."
"I am excited to join Todos Medical at a time when the Company is preparing to introduce TM-B1 and TM-B2, two revolutionary diagnostic assays for cancer detection, to the market. The market launch of a diagnostic product requires coordination among commercial sales, regulatory, and reimbursement strategies, as well as other important considerations," stated Dr. Bier. "I am looking forward to helping the Todos Medical team make value-building decisions for both the short-term and long-term success of the Company and its shareholders."
http://investor.todosmedical.com/news-release...-directors
Aloha
March 27, 2019 at 8:00 AM EDT
REHOVOT, Israel, March 27, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced the appointment of Dr. Colin Bier to its Board of Directors. Dr. Bier has over 35 years of clinical expertise having participated in numerous clinical trials, including trials in Alzheimer's disease, as well as experience in commercializing diagnostic tests.
"Dr. Bier brings expertise to the Company in the commercialization of diagnostic tests, including navigating the intricacies of CLIA and the FDA, and bringing diagnostic tests to market," said Dr. Herman Weiss, CEO of Todos Medical. "As Dr. Bier has previously served in the roles of Scientific Advisor and Chief Development Officer of Amarantus Diagnostics, his familiarity with our recent joint venture surrounding the science of LymPro, a diagnostic test for Alzheimer’s Disease, makes Colin an immediate asset to our organization. We believe his experience will be highly valuable as we navigate the regulatory landscape and seek to bring our diagnostic tests to the broader physician-patient community."
"I am excited to join Todos Medical at a time when the Company is preparing to introduce TM-B1 and TM-B2, two revolutionary diagnostic assays for cancer detection, to the market. The market launch of a diagnostic product requires coordination among commercial sales, regulatory, and reimbursement strategies, as well as other important considerations," stated Dr. Bier. "I am looking forward to helping the Todos Medical team make value-building decisions for both the short-term and long-term success of the Company and its shareholders."
http://investor.todosmedical.com/news-release...-directors
Aloha
(0)
(0)
